2 nominees · 3 ballot items.
Election of two Class I directors; advisory (non-binding) approval of the Company’s executive compensation (say-on-pay); and ratification of the appointment of the Company’s independent registered public accounting firm (PwC).
Election of two Class I directors (Elizabeth K. Arnold and Claudia P. Poccia) to serve until the 2029 Annual Meeting.
Non-binding, advisory vote to approve the compensation of the Named Executive Officers as disclosed in the proxy statement (say-on-pay).
This proposal asks stockholders to cast a non-binding advisory vote to approve the Company’s 2025 executive compensation for Named Executive Officers as disclosed in the proxy statement. Management is seeking this approval to validate its pay philosophy and approach—linking pay to performance through base salary, short-term incentives, and long-term equity incentives (RSUs and PSUs) tied to operating income, cash flow, revenue growth, EPS, and relative TSR—while retaining flexibility to consider stockholder feedback. The Compensation Committee, advised by an independent consultant, sets targets and designs incentive structures to align executive rewards with strategic priorities and stockholder returns; it also reviews comparator groups and applies rigorous personal performance assessments. The Board recommends a vote FOR because it believes the compensation program is competitive, aligned with long-term stockholder interests, includes performance-based components and robust governance (clawback, stock ownership guidelines). The vote is advisory but will inform future compensation decisions and the Committee considers past strong say-on-pay support as part of its review. The proposal’s context includes Innospec’s 2025 financial performance, specific incentive thresholds and PSP metrics, and the Committee’s recent adjustments to the MICP (e.g., lowering the corporate operating income threshold from 90% to 80%).
Ratify the appointment of PricewaterhouseCoopers LLP (PwC) as Innospec’s independent registered public accounting firm for fiscal year 2026.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | 10.58% | 2,605,126 | $190M |
| 2 | Allspring Global Investments Holdings, LLC | 9.39% | 2,314,027 | $170M |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 7.55% | 1,860,091 | $136M |
| 4 | DIMENSIONAL FUND ADVISORS LP | 4.81% | 1,185,147 | $87M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 4.53% | 1,114,598 | $81M |
| 6 | STATE STREET CORP | 3.92% | 964,335 | $70M |
| 7 | VICTORY CAPITAL MANAGEMENT INC | 3.51% | 864,994 | $63M |
| 8 | BlackRock, Inc. | 3.19% | 785,939 | $57M |
| 9 | TWO SIGMA INVESTMENTS, LP | 2.41% | 593,039 | $43M |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 2.21% | 543,210 | $40M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.